Cost-benefit analysis of haemodialysis in patients with end-stage kidney disease in Abuja, Nigeria
Open Access
- 3 July 2024
- journal article
- research article
- Published by Springer Nature in Health Economics Review
- Vol. 14 (1) , 1-8
Abstract
Background: Significant gaps in scholarship on the cost-benefit analysis of haemodialysis exist in low-middle-income countries, including Nigeria. The study, therefore, assessed the cost-benefit of haemodialysis compared with comprehensive conservative care (CCC) to determine if haemodialysis is socially worthwhile and justifies public funding in Nigeria. Methods: The study setting is Abuja, Nigeria. The study used a mixed-method design involving primary data collection and analysis of secondary data from previous studies. We adopted an ingredient-based costing approach. The mean costs and benefits of haemodialysis were derived from previous studies. The mean costs and benefits of CCC were obtained from a primary cross-sectional survey. We estimated the benefit-cost ratios (BCR) and net benefits to determine the social value of the two interventions. Results: The net benefit of haemodialysis (2,251.30) was positive, while that of CCC was negative (-1,197.19). The benefit-cost ratio of haemodialysis was 1.09, while that of CCC was 0.66. The probabilistic and one-way sensitivity analyses results demonstrate that haemodialysis was more cost-beneficial than CCC, and the BCRs of haemodialysis remained above one in most scenarios, unlike CCC’s BCR. Conclusion: The benefit of haemodialysis outweighs its cost, making it cost-beneficial to society and justifying public funding. However, the National Health Insurance Authority requires additional studies, such as budget impact analysis, to establish the affordability of full coverage of haemodialysis.Keywords
This publication has 25 references indexed in Scilit:
- Willingness to pay for haemodialysis among patients with chronic kidney disease in Abuja, NigeriaBMC Nephrology, 2024
- The prevalence of chronic kidney disease in South Africa - limitations of studies comparing prevalence with sub-Saharan Africa, Africa, and globallyBMC Nephrology, 2023
- Use of Productivity Loss/Gain in Cost-Effectiveness Analyses for Drugs: A Systematic ReviewPharmacoEconomics, 2020
- Dispelling the myths of providing dialysis in low- and middle-income countriesNature Reviews Nephrology, 2020
- Increasing access to integrated ESKD care as part of universal health coverageKidney International, 2019
- Global access of patients with kidney disease to health technologies and medications: findings from the Global Kidney Health Atlas projectKidney International Supplements, 2018
- Cost of hemodialysis in a public sector tertiary hospital of IndiaClinical Kidney Journal, 2018
- A Cost-Benefit Analysis of Two Alternative Models of Maternity Care in IrelandApplied Health Economics and Health Policy, 2017
- Chronic kidney disease in low-income to middle-income countries: the case for increased screeningBMJ Global Health, 2017
- Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness AnalysesJAMA, 2016